Patients with multiple sclerosis (MS) treated with alemtuzumab show sustained reduction in relapses and disability after five years, according to results reported at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting (14 October; Gothenburg, Sweden). The CAMMS223 study randomised 334 patients with early, active relapsing remitting MS to alemtuzumab (at… Continue reading